文献速递泌尿男性生殖肿瘤

围手术期纳武利尤单抗联合GC新辅助治疗肌层浸润性膀胱癌的III期试验最终结果

Neoadjuvant nivolumab plus gemcitabine-cisplatin followed by postsurgical adjuvant nivolumab versus neoadjuvant gemcitabine-cisplatin in patients with muscle-invasive bladder cancer: final results from the phase III CA017-078 trial.
PubMed 文献 · Ann Oncol · 2026-12-31

CA017-078(ENERGIZE)III期试验在初治可切除肌层浸润性膀胱癌(MIBC)患者中比较围手术期纳武利尤单抗联合新辅助吉西他滨-顺铂(GC)后手术及辅助纳武利尤单抗 vs 单纯新辅助GC后手术。最终分析中位随访54.5个月,纳武利尤单抗联合GC组pCR率39.1% vs GC组29.6%(校正差值9.5%,99.91%CI -2.6-21.6),EFS无改善(HR 0.94,95.74%CI 0.71-1.25;P=0.6697),OS因EFS未达检验标准仅描述性汇总(HR 0.88,95%CI 0.64-1.21)。

要点

  • 围手术期纳武利尤单抗联合GC未改善EFS,pCR率数值提高但差异无统计学意义。
  • 两组3-4级治疗相关不良事件发生率相似(50.0% vs 49.5%),联合组发生1例治疗相关死亡。
  • 探索性分析显示基线及C4D1 ctDNA阳性与更短EFS和OS相关。

核心结论

  • 在初治可切除MIBC中,新辅助GC基础上加用围手术期纳武利尤单抗未改善EFS,pCR率数值提高但差异无统计学意义。
  • 围手术期纳武利尤单抗联合GC的毒性可预期,与单纯GC相比3-4级治疗相关不良事件发生率相似。
  • 探索性分析提示ctDNA在基线及C4D1可检测与更短EFS和OS相关。

研究设计与样本

  • III期随机对照试验CA017-078(ENERGIZE),纳入初治、可切除cT2-T4aN0M0 MIBC且适合根治性膀胱切除和顺铂的患者。
  • 患者随机分配至新辅助纳武利尤单抗联合GC后手术及辅助纳武利尤单抗组(纳武利尤单抗联合GC组,325例)或新辅助GC后手术组(GC组,328例)。
  • 共同主要终点为pCR(定义为ypT0N0)和EFS;OS为预设分层检验策略内的次要终点,仅在EFS达统计学显著后才进行正式检验。

主要发现

  • 最终分析中位随访54.5个月,纳武利尤单抗联合GC组pCR率39.1%,GC组29.6%(校正差值9.5%,99.91%CI -2.6-21.6)。
  • EFS未改善:两组各104例事件,HR 0.94(95.74%CI 0.71-1.25;P=0.6697)。
  • OS因EFS未达检验标准仅描述性汇总:HR 0.88(95%CI 0.64-1.21)。
  • 3-4级治疗相关不良事件发生率纳武利尤单抗联合GC组50.0%,GC组49.5%;联合组发生1例治疗相关死亡。
  • 基线ctDNA阳性率总体55%(229/416),GC组51%(108/211),纳武利尤单抗联合GC组59%(121/205);C4D1清除率总体76.9%(153/199),联合组81.3%(87/107),GC组71.7%(66/92)。

临床怎么用

  • 该方案未显示EFS获益,不支持在初治可切除MIBC中常规于新辅助GC基础上加用围手术期纳武利尤单抗。
  • ctDNA基线及C4D1检测具有预后价值,可用于风险分层探索,但尚不能据此改变治疗决策。

局限性

  • OS因EFS未达检验标准仅作描述性汇总,未进行正式统计学检验。
  • ctDNA分析为探索性,样本量及检测时间点有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Perioperative immune-checkpoint inhibition improves outcomes in muscle-invasive bladder cancer (MIBC). The phase III, randomized CA017-078 (ENERGIZE) trial evaluated perioperative nivolumab plus neoadjuvant gemcitabine-cisplatin (GC) versus neoadjuvant GC alone for previously untreated, resectable MIBC. PATIENTS AND METHODS: Adults with previously untreated cT2-T4aN0M0 MIBC eligible for radical cystectomy (RC) and cisplatin were randomized to neoadjuvant nivolumab plus GC followed by RC and adjuvant nivolumab (nivolumab plus GC arm), or neoadjuvant GC followed by RC alone (GC arm). Co-primary endpoints were pathological complete response (pCR; defined as ypT0N0) and event-free survival (EFS). Overall survival (OS) was a secondary endpoint within the prespecified hierarchical testing strategy, and formal testing was contingent on a statistically significant EFS result. RESULTS: At this final analysis with 54.5 months of median follow-up, 325 patients were randomized to the nivolumab plus GC arm, 328 to the GC arm. pCR rates were 39.1% and 29.6%, respectively (adjusted difference 9.5%, 99.91% CI -2.6-21.6). EFS was not improved in the nivolumab plus GC versus GC arm (104 events in each arm; HR 0.94, 95.74% CI 0.71-1.25; P=0.6697). OS was summarized descriptively because EFS did not meet the testing criterion (HR 0.88, 95% CI 0.64-1.21). Grade 3-4 treatment-related adverse events occurred in 50.0% versus 49.5%; one treatment-related death occurred with nivolumab plus GC. Pretreatment ctDNA was positive in 229/416 tested patients (55%) overall, 108/211 (51%) in the GC arm, and 121/205 (59%) in the nivolumab plus GC arm. Clearance by cycle 4 day 1 (C4D1) occurred in 153/199 patients (76.9%) overall, 87/107 (81.3%) with nivolumab plus GC, and 66/92 (71.7%) with GC. ctDNA detection at baseline and at C4D1 was associated with shorter EFS and OS. CONCLUSIONS: The addition of perioperative nivolumab to neoadjuvant GC did not improve outcomes and was associated with predictable toxicity. Exploratory analysis showed ctDNA was strongly prognostic.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Sonpavde G, van der Heijden MS, Gupta S, et al. Neoadjuvant nivolumab plus gemcitabine-cisplatin followed by postsurgical adjuvant nivolumab versus neoadjuvant gemcitabine-cisplatin in patients with muscle-invasive bladder cancer: final results from the phase III CA017-078 trial. Ann Oncol. 2026. PMID: 42918420. doi:10.1016/j.annonc.2026.10.096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。